Enlivex Therapeutics Ltd.

ENLV

IL0011319527

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:30:00 2024-07-16 EDT			5-day change	1st Jan Change
1.41 ^USD	0.00%		+3.68%	-47.78%

06-30	Enlivex Therapeutics Ltd.'s Equity Buyback announced on August 30, 2023 has expired.	CI
06-24	Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial	MT

Enlivex Therapeutics Ltd.'s Equity Buyback announced on August 30, 2023 has expired.

June 29, 2024

The company expired its plan on June 2024.

Latest news about Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd.'s Equity Buyback announced on August 30, 2023 has expired.	06-29	CI
Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial	06-24	MT
Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis	06-24	CI
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis	06-17	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	06-14	CI
HC Wainwright Adjusts Price Target on Enlivex Therapeutics to $6 From $7, Maintains Buy Rating	06-11	MT
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis	06-03	CI
Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall	05-28	MT
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.	04-30	CI
Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	04-22	MT
Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis	04-22	CI
Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark	04-16	MT
Enlivex Therapeutics Ltd Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	04-16	CI
HC Wainwright Adjusts Enlivex Therapeutics Price Target to $7 From $12, Maintains Buy Rating	04-12	MT
Sector Update: Health Care Stocks Softer Late Afternoon	04-11	MT
Sector Update: Health Care	04-11	MT
Enlivex Therapeutics Shares Fall After Topline Data from Sepsis Treatment Study	04-11	MT
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra? in Patients with Sepsis	04-11	CI
Tranche Update on Enlivex Therapeutics Ltd.'s Equity Buyback Plan announced on September 18, 2023.	03-29	CI
Enlivex Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29	CI
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	02-07	CI
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis	01-17	CI
Enlivex Therapeutics Ltd.'s Equity Buyback Plan Extended till June 30, 2024.	01-16	CI
Top Midday Gainers	12-20	MT
Enlivex Therapeutics Ltd. Announces Completion of Enrollment of its Phase II Trial Evaluating Allocetra in Patients with Sepsis	12-20	CI

Chart Enlivex Therapeutics Ltd.

Duration

Period

More charts

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Sector

Biotechnology & Medical Research

Calendar

2025-05-22 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.41 USD

Average target price

6 USD

Spread / Average Target

+325.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ENLIVEX THERAPEUTICS LTD.	-47.78%	29.43M
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
BIONTECH SE	-17.74%	20.33B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B

Bio Therapeutic Drugs